LENZ THERAPEUTICS INC (LENZ) Fundamental Analysis & Valuation

NASDAQ:LENZ • US52635N1037

Current stock price

8.4 USD
-0.54 (-6.04%)
At close:
8.5 USD
+0.1 (+1.19%)
After Hours:

This LENZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LENZ Profitability Analysis

1.1 Basic Checks

  • LENZ had negative earnings in the past year.
  • LENZ had a negative operating cash flow in the past year.
  • LENZ had negative earnings in each of the past 5 years.
  • In the past 5 years LENZ always reported negative operating cash flow.
LENZ Yearly Net Income VS EBIT VS OCF VS FCFLENZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -26.85%, LENZ is in line with its industry, outperforming 57.51% of the companies in the same industry.
  • LENZ's Return On Equity of -28.88% is fine compared to the rest of the industry. LENZ outperforms 65.28% of its industry peers.
Industry RankSector Rank
ROA -26.85%
ROE -28.88%
ROIC N/A
ROA(3y)-38.7%
ROA(5y)-33.02%
ROE(3y)-40.39%
ROE(5y)-34.74%
ROIC(3y)N/A
ROIC(5y)N/A
LENZ Yearly ROA, ROE, ROICLENZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

  • The Profit Margin and Operating Margin are not available for LENZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LENZ Yearly Profit, Operating, Gross MarginsLENZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. LENZ Health Analysis

2.1 Basic Checks

  • LENZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LENZ has been increased compared to 1 year ago.
  • The number of shares outstanding for LENZ has been reduced compared to 5 years ago.
  • There is no outstanding debt for LENZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LENZ Yearly Shares OutstandingLENZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
LENZ Yearly Total Debt VS Total AssetsLENZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 6.46 indicates that LENZ is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.46, LENZ belongs to the top of the industry, outperforming 87.56% of the companies in the same industry.
  • LENZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.46
ROIC/WACCN/A
WACC9.31%
LENZ Yearly LT Debt VS Equity VS FCFLENZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • LENZ has a Current Ratio of 14.23. This indicates that LENZ is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 14.23, LENZ belongs to the top of the industry, outperforming 92.23% of the companies in the same industry.
  • A Quick Ratio of 14.09 indicates that LENZ has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 14.09, LENZ belongs to the best of the industry, outperforming 92.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.23
Quick Ratio 14.09
LENZ Yearly Current Assets VS Current LiabilitesLENZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. LENZ Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.51% over the past year.
EPS 1Y (TTM)41.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-152.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • LENZ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.90% yearly.
  • The Revenue is expected to grow by 85.36% on average over the next years. This is a very strong growth
EPS Next Y-9.4%
EPS Next 2Y28.37%
EPS Next 3Y38.38%
EPS Next 5Y32.9%
Revenue Next Year157.22%
Revenue Next 2Y163.69%
Revenue Next 3Y128.56%
Revenue Next 5Y85.36%

3.3 Evolution

LENZ Yearly Revenue VS EstimatesLENZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
LENZ Yearly EPS VS EstimatesLENZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. LENZ Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LENZ. In the last year negative earnings were reported.
  • Also next year LENZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LENZ Price Earnings VS Forward Price EarningsLENZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LENZ Per share dataLENZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • LENZ's earnings are expected to grow with 38.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.37%
EPS Next 3Y38.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LENZ Dividend Analysis

5.1 Amount

  • No dividends for LENZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LENZ Fundamentals: All Metrics, Ratios and Statistics

LENZ THERAPEUTICS INC

NASDAQ:LENZ (3/27/2026, 8:00:03 PM)

After market: 8.5 +0.1 (+1.19%)

8.4

-0.54 (-6.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-24
Earnings (Next)05-04
Inst Owners116.17%
Inst Owner Change18.5%
Ins Owners2.52%
Ins Owner Change-9.86%
Market Cap262.84M
Revenue(TTM)19.09M
Net Income(TTM)-82.13M
Analysts87.69
Price Target49.16 (485.24%)
Short Float %29.24%
Short Ratio9.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.5%
Min EPS beat(2)-17.11%
Max EPS beat(2)18.1%
EPS beat(4)3
Avg EPS beat(4)6.29%
Min EPS beat(4)-17.11%
Max EPS beat(4)18.1%
EPS beat(8)5
Avg EPS beat(8)-31.96%
EPS beat(12)5
Avg EPS beat(12)-62.38%
EPS beat(16)8
Avg EPS beat(16)-46.78%
Revenue beat(2)1
Avg Revenue beat(2)31.05%
Min Revenue beat(2)-17.36%
Max Revenue beat(2)79.47%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.92%
PT rev (3m)-9.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.02%
EPS NY rev (1m)-1.31%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.77
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-2.79
EYN/A
EPS(NY)-3.05
Fwd EYN/A
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.21
OCFYN/A
SpS0.61
BVpS9.09
TBVpS9.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.85%
ROE -28.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.81%
FCFM N/A
ROA(3y)-38.7%
ROA(5y)-33.02%
ROE(3y)-40.39%
ROE(5y)-34.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 288.15%
Cap/Sales 4.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.23
Quick Ratio 14.09
Altman-Z 6.46
F-Score4
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)515.36%
Cap/Depr(5y)522.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-152.17%
EPS Next Y-9.4%
EPS Next 2Y28.37%
EPS Next 3Y38.38%
EPS Next 5Y32.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year157.22%
Revenue Next 2Y163.69%
Revenue Next 3Y128.56%
Revenue Next 5Y85.36%
EBIT growth 1Y-55.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.47%
OCF growth 3YN/A
OCF growth 5YN/A

LENZ THERAPEUTICS INC / LENZ Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for LENZ THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to LENZ.


Can you provide the valuation status for LENZ THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to LENZ THERAPEUTICS INC (LENZ). This can be considered as Overvalued.


Can you provide the profitability details for LENZ THERAPEUTICS INC?

LENZ THERAPEUTICS INC (LENZ) has a profitability rating of 1 / 10.